Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL
- Status
- COMPLETED
- Phase
- PHASE2
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Ph II CHOP+Velcade in Mediastinal LBCL
- Status
- TERMINATED
- Phase
- PHASE2
Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE2
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse
- Status
- COMPLETED
- Phase
- PHASE2
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)
- Status
- UNKNOWN
- Phase
- PHASE2
Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1